Reports

Industry Research Reports

description

Part 1

description

Part 2

description

Part 3

description

Part 5

Global and United States Tyrosine Kinase JAK Inhibitors Market Report & Forecast 2022-2028

Global and United States Tyrosine Kinase JAK Inhibitors Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2021-12-29

Pages: 100 Pages

Report ld: 170611

  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

Market Analysis and Insights: Global and United States Tyrosine Kinase JAK Inhibitors Market
This report focuses on global and United States Tyrosine Kinase JAK Inhibitors market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Tyrosine Kinase JAK Inhibitors market size is estimated to be worth US$ 47210 million in 2022 and is forecast to a readjusted size of US$ 550830 million by 2028 with a CAGR of 50.6% during the review period. Fully considering the economic change by this health crisis, by Type, Tofacitinib accounting for % of the Tyrosine Kinase JAK Inhibitors global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Rheumatoid Arthritis (RA) was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.

Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.

North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%. 
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42%  market sharers.

Global Tyrosine Kinase JAK Inhibitors Scope and Market Size
Tyrosine Kinase JAK Inhibitors market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Tyrosine Kinase JAK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Tyrosine Kinase JAK Inhibitors market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Tyrosine Kinase JAK Inhibitors market is segmented into
    Tofacitinib
    Ruxolitinib
    Baricitinib

Segment by Application, the Tyrosine Kinase JAK Inhibitors market is segmented into
    Rheumatoid Arthritis (RA)
    Polycythemia Vera (PCV)
    Myelofibrosis (MF)
    Others

Regional and Country-level Analysis
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E

Competitive Landscape and Tyrosine Kinase JAK Inhibitors Market Share Analysis
Tyrosine Kinase JAK Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Tyrosine Kinase JAK Inhibitors business, the date to enter into the Tyrosine Kinase JAK Inhibitors market, Tyrosine Kinase JAK Inhibitors product introduction, recent developments, etc.

The major vendors covered:
    Pfizer
    Incyte
    Novartis
    Eli Lilly
    Gilead
    Sanofi
    Galapagos
    AbbVie
    Vertex
    Teva
    Astellas Pharma
    Celgene
    CTI BioPharma
 1 Study Coverage
1.1 Tyrosine Kinase JAK Inhibitors Product Introduction
1.2 Global Tyrosine Kinase JAK Inhibitors Outlook 2017 VS 2022 VS 2028
1.2.1 Global Tyrosine Kinase JAK Inhibitors Sales in US$ Million for the Year 2017-2028
1.2.2 Global Tyrosine Kinase JAK Inhibitors Sales in Volume for the Year 2017-2028
1.3 United States Tyrosine Kinase JAK Inhibitors Outlook 2017 VS 2022 VS 2028
1.3.1 United States Tyrosine Kinase JAK Inhibitors Sales in US$ Million for the Year 2017-2028
1.3.2 United States Tyrosine Kinase JAK Inhibitors Sales in Volume for the Year 2017-2028
1.4 Tyrosine Kinase JAK Inhibitors Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Tyrosine Kinase JAK Inhibitors in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Tyrosine Kinase JAK Inhibitors Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Tyrosine Kinase JAK Inhibitors Market Dynamics
1.5.1 Tyrosine Kinase JAK Inhibitors Industry Trends
1.5.2 Tyrosine Kinase JAK Inhibitors Market Drivers
1.5.3 Tyrosine Kinase JAK Inhibitors Market Challenges
1.5.4 Tyrosine Kinase JAK Inhibitors Market Restraints
1.6 Study Objectives
1.7 Years Considered

 2 Market by Type
2.1 Tyrosine Kinase JAK Inhibitors Market Segment by Type
2.1.1 Tofacitinib
2.1.2 Ruxolitinib
2.1.3 Baricitinib
2.2 Global Tyrosine Kinase JAK Inhibitors Market Size by Type
2.2.1 Global Tyrosine Kinase JAK Inhibitors Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Tyrosine Kinase JAK Inhibitors Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Tyrosine Kinase JAK Inhibitors Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Tyrosine Kinase JAK Inhibitors Market Size by Type
2.3.1 United States Tyrosine Kinase JAK Inhibitors Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Tyrosine Kinase JAK Inhibitors Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Tyrosine Kinase JAK Inhibitors Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
3.1 Tyrosine Kinase JAK Inhibitors Market Segment by Application
3.1.1 Rheumatoid Arthritis (RA)
3.1.2 Polycythemia Vera (PCV)
3.1.3 Myelofibrosis (MF)
3.1.4 Others
3.2 Global Tyrosine Kinase JAK Inhibitors Market Size by Application
3.2.1 Global Tyrosine Kinase JAK Inhibitors Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Tyrosine Kinase JAK Inhibitors Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Tyrosine Kinase JAK Inhibitors Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Tyrosine Kinase JAK Inhibitors Market Size by Application
3.3.1 United States Tyrosine Kinase JAK Inhibitors Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Tyrosine Kinase JAK Inhibitors Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Tyrosine Kinase JAK Inhibitors Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Tyrosine Kinase JAK Inhibitors Competitor Landscape by Company
4.1 Global Tyrosine Kinase JAK Inhibitors Market Size by Company
4.1.1 Top Global Tyrosine Kinase JAK Inhibitors Manufacturers Ranked by Revenue (2021)
4.1.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2017-2022)
4.1.3 Global Tyrosine Kinase JAK Inhibitors Sales by Manufacturer (2017-2022)
4.1.4 Global Tyrosine Kinase JAK Inhibitors Price by Manufacturer (2017-2022)
4.2 Global Tyrosine Kinase JAK Inhibitors Concentration Ratio (CR)
4.2.1 Tyrosine Kinase JAK Inhibitors Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Tyrosine Kinase JAK Inhibitors in 2021
4.2.3 Global Tyrosine Kinase JAK Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Tyrosine Kinase JAK Inhibitors Manufacturing Base Distribution, Product Type
4.3.1 Global Tyrosine Kinase JAK Inhibitors Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Tyrosine Kinase JAK Inhibitors Product Type
4.3.3 Date of International Manufacturers Enter into Tyrosine Kinase JAK Inhibitors Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Tyrosine Kinase JAK Inhibitors Market Size by Company
4.5.1 Top Tyrosine Kinase JAK Inhibitors Players in United States, Ranked by Revenue (2021)
4.5.2 United States Tyrosine Kinase JAK Inhibitors Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Tyrosine Kinase JAK Inhibitors Sales by Players (2020, 2021 & 2022)

 5 Global Tyrosine Kinase JAK Inhibitors Market Size by Region
5.1 Global Tyrosine Kinase JAK Inhibitors Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Tyrosine Kinase JAK Inhibitors Market Size in Volume by Region (2017-2028)
5.2.1 Global Tyrosine Kinase JAK Inhibitors Sales in Volume by Region: 2017-2022
5.2.2 Global Tyrosine Kinase JAK Inhibitors Sales in Volume Forecast by Region (2023-2028)
5.3 Global Tyrosine Kinase JAK Inhibitors Market Size in Value by Region (2017-2028)
5.3.1 Global Tyrosine Kinase JAK Inhibitors Sales in Value by Region: 2017-2022
5.3.2 Global Tyrosine Kinase JAK Inhibitors Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Tyrosine Kinase JAK Inhibitors Market Size YoY Growth 2017-2028
6.1.2 North America Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Tyrosine Kinase JAK Inhibitors Market Size YoY Growth 2017-2028
6.3.2 Europe Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Tyrosine Kinase JAK Inhibitors Market Size YoY Growth 2017-2028
6.4.2 Latin America Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E

 7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Products Offered
7.1.5 Pfizer Recent Development
7.2 Incyte
7.2.1 Incyte Corporation Information
7.2.2 Incyte Description and Business Overview
7.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Incyte Tyrosine Kinase JAK Inhibitors Products Offered
7.2.5 Incyte Recent Development
7.3 Novartis
7.3.1 Novartis Corporation Information
7.3.2 Novartis Description and Business Overview
7.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Novartis Tyrosine Kinase JAK Inhibitors Products Offered
7.3.5 Novartis Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Corporation Information
7.4.2 Eli Lilly Description and Business Overview
7.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Products Offered
7.4.5 Eli Lilly Recent Development
7.5 Gilead
7.5.1 Gilead Corporation Information
7.5.2 Gilead Description and Business Overview
7.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Gilead Tyrosine Kinase JAK Inhibitors Products Offered
7.5.5 Gilead Recent Development
7.6 Sanofi
7.6.1 Sanofi Corporation Information
7.6.2 Sanofi Description and Business Overview
7.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Products Offered
7.6.5 Sanofi Recent Development
7.7 Galapagos
7.7.1 Galapagos Corporation Information
7.7.2 Galapagos Description and Business Overview
7.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Products Offered
7.7.5 Galapagos Recent Development
7.8 AbbVie
7.8.1 AbbVie Corporation Information
7.8.2 AbbVie Description and Business Overview
7.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Products Offered
7.8.5 AbbVie Recent Development
7.9 Vertex
7.9.1 Vertex Corporation Information
7.9.2 Vertex Description and Business Overview
7.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Vertex Tyrosine Kinase JAK Inhibitors Products Offered
7.9.5 Vertex Recent Development
7.10 Teva
7.10.1 Teva Corporation Information
7.10.2 Teva Description and Business Overview
7.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Teva Tyrosine Kinase JAK Inhibitors Products Offered
7.10.5 Teva Recent Development
7.11 Astellas Pharma
7.11.1 Astellas Pharma Corporation Information
7.11.2 Astellas Pharma Description and Business Overview
7.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Products Offered
7.11.5 Astellas Pharma Recent Development
7.12 Celgene
7.12.1 Celgene Corporation Information
7.12.2 Celgene Description and Business Overview
7.12.3 Celgene Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Celgene Products Offered
7.12.5 Celgene Recent Development
7.13 CTI BioPharma
7.13.1 CTI BioPharma Corporation Information
7.13.2 CTI BioPharma Description and Business Overview
7.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2017-2022)
7.13.4 CTI BioPharma Products Offered
7.13.5 CTI BioPharma Recent Development

 8 Industry Chain and Sales Channels Analysis
8.1 Tyrosine Kinase JAK Inhibitors Industry Chain Analysis
8.2 Tyrosine Kinase JAK Inhibitors Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Tyrosine Kinase JAK Inhibitors Distributors
8.3 Tyrosine Kinase JAK Inhibitors Production Mode & Process
8.4 Tyrosine Kinase JAK Inhibitors Sales and Marketing
8.4.1 Tyrosine Kinase JAK Inhibitors Sales Channels
8.4.2 Tyrosine Kinase JAK Inhibitors Distributors
8.5 Tyrosine Kinase JAK Inhibitors Customers

 9 Research Findings and Conclusion

 10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Tyrosine Kinase JAK Inhibitors CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Tyrosine Kinase JAK Inhibitors Market Trends
    Table 3. Tyrosine Kinase JAK Inhibitors Market Drivers
    Table 4. Tyrosine Kinase JAK Inhibitors Market Challenges
    Table 5. Tyrosine Kinase JAK Inhibitors Market Restraints
    Table 6. Global Tyrosine Kinase JAK Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Tyrosine Kinase JAK Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Tyrosine Kinase JAK Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Tyrosine Kinase JAK Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Tyrosine Kinase JAK Inhibitors Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Tyrosine Kinase JAK Inhibitors Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Tyrosine Kinase JAK Inhibitors Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Tyrosine Kinase JAK Inhibitors Sales Share by Manufacturer, 2017-2022
    Table 15. Global Tyrosine Kinase JAK Inhibitors Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Tyrosine Kinase JAK Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Tyrosine Kinase JAK Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tyrosine Kinase JAK Inhibitors as of 2021)
    Table 18. Top Players of Tyrosine Kinase JAK Inhibitors in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Tyrosine Kinase JAK Inhibitors Product Type
    Table 20. Date of International Manufacturers Enter into Tyrosine Kinase JAK Inhibitors Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Tyrosine Kinase JAK Inhibitors Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Tyrosine Kinase JAK Inhibitors Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Tyrosine Kinase JAK Inhibitors Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Tyrosine Kinase JAK Inhibitors Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Tyrosine Kinase JAK Inhibitors Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Tyrosine Kinase JAK Inhibitors Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Tyrosine Kinase JAK Inhibitors Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Tyrosine Kinase JAK Inhibitors Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Tyrosine Kinase JAK Inhibitors Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Tyrosine Kinase JAK Inhibitors Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Tyrosine Kinase JAK Inhibitors Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Tyrosine Kinase JAK Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Tyrosine Kinase JAK Inhibitors Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Tyrosine Kinase JAK Inhibitors Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Tyrosine Kinase JAK Inhibitors Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Tyrosine Kinase JAK Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Tyrosine Kinase JAK Inhibitors Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Tyrosine Kinase JAK Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Pfizer Corporation Information
    Table 43. Pfizer Description and Business Overview
    Table 44. Pfizer Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Pfizer Tyrosine Kinase JAK Inhibitors Product
    Table 46. Pfizer Recent Development
    Table 47. Incyte Corporation Information
    Table 48. Incyte Description and Business Overview
    Table 49. Incyte Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Incyte Product
    Table 51. Incyte Recent Development
    Table 52. Novartis Corporation Information
    Table 53. Novartis Description and Business Overview
    Table 54. Novartis Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Novartis Product
    Table 56. Novartis Recent Development
    Table 57. Eli Lilly Corporation Information
    Table 58. Eli Lilly Description and Business Overview
    Table 59. Eli Lilly Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Eli Lilly Product
    Table 61. Eli Lilly Recent Development
    Table 62. Gilead Corporation Information
    Table 63. Gilead Description and Business Overview
    Table 64. Gilead Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Gilead Product
    Table 66. Gilead Recent Development
    Table 67. Sanofi Corporation Information
    Table 68. Sanofi Description and Business Overview
    Table 69. Sanofi Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Sanofi Product
    Table 71. Sanofi Recent Development
    Table 72. Galapagos Corporation Information
    Table 73. Galapagos Description and Business Overview
    Table 74. Galapagos Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. Galapagos Product
    Table 76. Galapagos Recent Development
    Table 77. AbbVie Corporation Information
    Table 78. AbbVie Description and Business Overview
    Table 79. AbbVie Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. AbbVie Product
    Table 81. AbbVie Recent Development
    Table 82. Vertex Corporation Information
    Table 83. Vertex Description and Business Overview
    Table 84. Vertex Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Vertex Product
    Table 86. Vertex Recent Development
    Table 87. Teva Corporation Information
    Table 88. Teva Description and Business Overview
    Table 89. Teva Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Teva Product
    Table 91. Teva Recent Development
    Table 92. Astellas Pharma Corporation Information
    Table 93. Astellas Pharma Description and Business Overview
    Table 94. Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 95. Astellas Pharma Product
    Table 96. Astellas Pharma Recent Development
    Table 97. Celgene Corporation Information
    Table 98. Celgene Description and Business Overview
    Table 99. Celgene Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 100. Celgene Product
    Table 101. Celgene Recent Development
    Table 102. CTI BioPharma Corporation Information
    Table 103. CTI BioPharma Description and Business Overview
    Table 104. CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 105. CTI BioPharma Product
    Table 106. CTI BioPharma Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Tyrosine Kinase JAK Inhibitors Customers List
    Table 110. Tyrosine Kinase JAK Inhibitors Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Tyrosine Kinase JAK Inhibitors Product Picture
    Figure 2. Global Tyrosine Kinase JAK Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Tyrosine Kinase JAK Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 4. Global Tyrosine Kinase JAK Inhibitors Sales 2017-2028 (K Units)
    Figure 5. United States Tyrosine Kinase JAK Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Tyrosine Kinase JAK Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 7. United States Tyrosine Kinase JAK Inhibitors Sales 2017-2028 (K Units)
    Figure 8. United States Tyrosine Kinase JAK Inhibitors Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Tyrosine Kinase JAK Inhibitors Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Tyrosine Kinase JAK Inhibitors Report Years Considered
    Figure 11. Product Picture of Tofacitinib
    Figure 12. Product Picture of Ruxolitinib
    Figure 13. Product Picture of Baricitinib
    Figure 14. Global Tyrosine Kinase JAK Inhibitors Market Share by Type in 2022 & 2028
    Figure 15. Global Tyrosine Kinase JAK Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 16. Global Tyrosine Kinase JAK Inhibitors Sales Market Share in Value by Type (2017-2028)
    Figure 17. Global Tyrosine Kinase JAK Inhibitors Sales by Type (2017-2028) & (K Units)
    Figure 18. Global Tyrosine Kinase JAK Inhibitors Sales Market Share in Volume by Type (2017-2028)
    Figure 19. Global Tyrosine Kinase JAK Inhibitors Price by Type (2017-2028) & (USD/Unit)
    Figure 20. United States Tyrosine Kinase JAK Inhibitors Market Share by Type in 2022 & 2028
    Figure 21. United States Tyrosine Kinase JAK Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 22. United States Tyrosine Kinase JAK Inhibitors Sales Market Share in Value by Type (2017-2028)
    Figure 23. United States Tyrosine Kinase JAK Inhibitors Sales by Type (2017-2028) & (K Units)
    Figure 24. United States Tyrosine Kinase JAK Inhibitors Sales Market Share in Volume by Type (2017-2028)
    Figure 25. United States Tyrosine Kinase JAK Inhibitors Price by Type (2017-2028) & (USD/Unit)
    Figure 26. Product Picture of Rheumatoid Arthritis (RA)
    Figure 27. Product Picture of Polycythemia Vera (PCV)
    Figure 28. Product Picture of Myelofibrosis (MF)
    Figure 29. Product Picture of Others
    Figure 30. Global Tyrosine Kinase JAK Inhibitors Market Share by Application in 2022 & 2028
    Figure 31. Global Tyrosine Kinase JAK Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 32. Global Tyrosine Kinase JAK Inhibitors Sales Market Share in Value by Application (2017-2028)
    Figure 33. Global Tyrosine Kinase JAK Inhibitors Sales by Application (2017-2028) & (K Units)
    Figure 34. Global Tyrosine Kinase JAK Inhibitors Sales Market Share in Volume by Application (2017-2028)
    Figure 35. Global Tyrosine Kinase JAK Inhibitors Price by Application (2017-2028) & (USD/Unit)
    Figure 36. United States Tyrosine Kinase JAK Inhibitors Market Share by Application in 2022 & 2028
    Figure 37. United States Tyrosine Kinase JAK Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 38. United States Tyrosine Kinase JAK Inhibitors Sales Market Share in Value by Application (2017-2028)
    Figure 39. United States Tyrosine Kinase JAK Inhibitors Sales by Application (2017-2028) & (K Units)
    Figure 40. United States Tyrosine Kinase JAK Inhibitors Sales Market Share in Volume by Application (2017-2028)
    Figure 41. United States Tyrosine Kinase JAK Inhibitors Price by Application (2017-2028) & (USD/Unit)
    Figure 42. North America Tyrosine Kinase JAK Inhibitors Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 43. North America Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 44. U.S. Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Canada Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Europe Tyrosine Kinase JAK Inhibitors Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 47. Europe Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. Germany Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. France Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. U.K. Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Italy Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Russia Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 54. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 55. China Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Japan Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. South Korea Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. India Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Australia Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Taiwan Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Indonesia Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Thailand Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Malaysia Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Philippines Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Latin America Tyrosine Kinase JAK Inhibitors Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 66. Latin America Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 67. Mexico Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Brazil Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Argentina Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 71. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Turkey Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Saudi Arabia Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. U.A.E Tyrosine Kinase JAK Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Tyrosine Kinase JAK Inhibitors Value Chain
    Figure 76. Tyrosine Kinase JAK Inhibitors Production Process
    Figure 77. Channels of Distribution
    Figure 78. Distributors Profiles
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

Market Analysis and Insights: Global and United States Tyrosine Kinase JAK Inhibitors Market
This report focuses on global and United States Tyrosine Kinase JAK Inhibitors market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Tyrosine Kinase JAK Inhibitors market size is estimated to be worth US$ 47210 million in 2022 and is forecast to a readjusted size of US$ 550830 million by 2028 with a CAGR of 50.6% during the review period. Fully considering the economic change by this health crisis, by Type, Tofacitinib accounting for % of the Tyrosine Kinase JAK Inhibitors global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Rheumatoid Arthritis (RA) was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.

Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.

North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%. 
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42%  market sharers.

Global Tyrosine Kinase JAK Inhibitors Scope and Market Size
Tyrosine Kinase JAK Inhibitors market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Tyrosine Kinase JAK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Tyrosine Kinase JAK Inhibitors market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Tyrosine Kinase JAK Inhibitors market is segmented into
    Tofacitinib
    Ruxolitinib
    Baricitinib

Segment by Application, the Tyrosine Kinase JAK Inhibitors market is segmented into
    Rheumatoid Arthritis (RA)
    Polycythemia Vera (PCV)
    Myelofibrosis (MF)
    Others

Regional and Country-level Analysis
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E

Competitive Landscape and Tyrosine Kinase JAK Inhibitors Market Share Analysis
Tyrosine Kinase JAK Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Tyrosine Kinase JAK Inhibitors business, the date to enter into the Tyrosine Kinase JAK Inhibitors market, Tyrosine Kinase JAK Inhibitors product introduction, recent developments, etc.

The major vendors covered:
    Pfizer
    Incyte
    Novartis
    Eli Lilly
    Gilead
    Sanofi
    Galapagos
    AbbVie
    Vertex
    Teva
    Astellas Pharma
    Celgene
    CTI BioPharma
Global and United States Tyrosine Kinase JAK Inhibitors Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2021-12-29

Pages: 100 Pages

Report ld: 170611

CHOOSE LICENSE TYPE
提示

USD 4350.00

提示

USD 6525.00

提示

USD 8700.00

/uploads/payment/payIcon/masterCard-01.svg/uploads/payment/payIcon/american-express-01.svg/uploads/payment/payIcon/visa-01.svg/uploads/payment/payIcon/diners-club-01.svg/uploads/payment/payIcon/discover-4-01.svg/uploads/payment/payIcon/jcb-01.svg
加入购物车

Add to Cart

立即购买

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

WHAT QYRESEARCH OFFER?
Competition

Competition

Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.

Industry Analysis

Industry Analysis

Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.

Market Size

Market Size

Capacity, production, sales, revenue, price, cost etc.

Customized Information

Customized Information

We can offer customized survey and information to meet ourclient's need.

INTEREST IN THIS REPORT?

Get A Free Sample >>
WHY QYR?
  • Fastest report delivery service

    Fastest report delivery service

  • More than 17 years of vast experience

    More than 17 years of vast experience

  • Operation for 24 * 7 & 365 days

    Operation for 24 * 7 & 365 days

  • In-depth and comprehensive analysis

    In-depth and comprehensive analysis

  • Professional and timely after-sales service

    Professional and timely after-sales service

  • Owns large database

    Owns large database

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

WHAT QYRESEARCH OFFER?
Competition

Competition

Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.

Industry Analysis

Industry Analysis

Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.

Market Size

Market Size

Capacity, production, sales, revenue, price, cost etc.

Customized Information

Customized Information

We can offer customized survey and information to meet ourclient's need.

INTEREST IN THIS REPORT?

Get A Free Sample >>
WHY QYR?
  • Fastest report delivery service

    Fastest report delivery service

  • More than 17 years of vast experience

    More than 17 years of vast experience

  • Operation for 24 * 7 & 365 days

    Operation for 24 * 7 & 365 days

  • In-depth and comprehensive analysis

    In-depth and comprehensive analysis

  • Professional and timely after-sales service

    Professional and timely after-sales service

  • Owns large database

    Owns large database

biaoTi

WORLD WIDE OFFICE

加入购物车

Add to Cart

立即购买

Buy Now